CARBOPLATINE HOSPIRA 10 mg/ml

DRUG4 trials

Sponsors

Institut Curie, Institut Curie, Intergroupe Francophone De Cancerologie Thoracique, Centre Regional Lutte Contre Le Cancer, Institut Curie

Conditions

Early and metastatic triple negative breast cancerHead and neck squamous cell carcinomaOcular conservative treatment for retinoblastomaadvanced ALK-positive non-small cell lung cancer

Phase 2

"SKYLINE": Tiragolumab and atezolizumab associated with chemotherapy in triple negative breast cancer: A phase II trial

RecruitingCTIS2022-501561-51-00

Institut Curie, Institut CurieEarly and metastatic triple negative breast cancer

Start: 2024-03-27Target: 160Updated: 2025-05-07

IFCT-2101 MASTERPROTOCOL ALK A phase II randomized, open-labelled, multicenter study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non-small cell lung cancer

Active, not recruitingCTIS2023-510387-13-00

Intergroupe Francophone De Cancerologie Thoraciqueadvanced ALK-positive non-small cell lung cancer

Start: 2022-05-18Target: 110Updated: 2025-02-11

RETINO 2018: conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome

RecruitingCTIS2024-514025-30-00

Institut CurieOcular conservative treatment for retinoblastoma

Start: 2021-03-25Target: 225Updated: 2024-05-31

Carboplatin + Paclitaxel + Cetuximab (PCC) after failure of first line Immune checkpoint inhibitor with or without chemotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck: CARPACCIO (CARboplatin PAClitaxel Cetuximab IO immuno-oncology)

RecruitingCTIS2024-512297-96-01

Centre Regional Lutte Contre Le CancerHead and neck squamous cell carcinoma

Start: 2024-11-26Target: 46Updated: 2026-01-16